Effect of new modalities of treatment on physicians' management plan for patients with spinal muscular atrophy
FA Bashiri, HA Idris, FM Al-Sohime, MH Temsah… - Neurosciences …, 2019 - nsj.org.sa
Objectives: To determine physicians' attitudes and stated practice in the management of
patients with spinal muscular atrophy (SMA). We also aimed to explore their knowledge …
patients with spinal muscular atrophy (SMA). We also aimed to explore their knowledge …
[PDF][PDF] Spinal muscular atrophy and communicating hydrocephalus: A novel or a well-established rare association?
FZ Alkhars, N Almajhad, J Al-Obaid, F Alghadeer… - Cureus, 2020 - cureus.com
Spinal muscular atrophy (SMA) is a genetic progressive neuromuscular disease
characterized by loss of motor neurons, which is linked to mutation of the survival motor …
characterized by loss of motor neurons, which is linked to mutation of the survival motor …
[HTML][HTML] Nusinersen in spinal muscular atrophy: Respiratory outcomes at tertiary care centers
F Alsohime, MH Temsah, M Al-Jelaify… - Journal of Nature and …, 2020 - journals.lww.com
Objectives: The objective of the study wasto describe the effect of nusinersen therapy and its
1 st-year associated outcomes, weaning of ventilator support, and length of stay in pediatric …
1 st-year associated outcomes, weaning of ventilator support, and length of stay in pediatric …
